Trial Profile
A 12 Week, Open-Label, Study to Evaluate the Effectiveness of Dorzolamide-Timolol as First Line Therapy to Reduce Intraocular Pressure in Patients With Untreated Open Angle Glaucoma (OAG) or Ocular Hypertension (OH)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Dorzolamide/timolol (Primary) ; Prostaglandins
- Indications Glaucoma; Ocular hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 08 May 2014 New trial record